Aclarion Responds to Echo Lake's $4.00 Per Share Acquisition Offer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2026
0mins
Aclarion issued the following statement in response to the press release issued by Echo Lake Capital and its offer to acquire the company for $4.00 per share in cash and contingent value rights: "Aclarion's Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders. We regularly review our strategic priorities and evaluate opportunities to enhance value for all stakeholders. To that end, the Board of Directors will carefully review and evaluate Echo Lake's proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders. The Board authorized a share repurchase program underscoring our conviction that Aclarion's current market valuation does not fully reflect the strength of our platform or the long-term opportunity ahead. This action also reflects our commitment to deploying capital in ways that serve the interests of all shareholders while continuing to invest in our business. The Company notes that the Echo Lake communication contains numerous assertions regarding governance and other matters that lack important context and are presented in a manner that the Board believes is misleading. Aclarion's Board comprises seven highly qualified directors with relevant expertise in healthcare, regulatory affairs, technology investing, payer contracting, public company leadership and scaling medical technologies. The Board is committed to ongoing Board enhancement and regularly evaluates its composition to ensure it brings the fresh perspectives and appropriate skills necessary to drive value creation for all Aclarion shareholders. Accordingly, five new directors have been appointed within the last six years, all of whom bring diverse perspectives that directly align with Aclarion's strategic priorities."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACON
Wall Street analysts forecast ACON stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.110
Low
23.00
Averages
23.00
High
23.00
Current: 3.110
Low
23.00
Averages
23.00
High
23.00
No data
About ACON
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aclarion to Present at Planet MicroCap Las Vegas 2026
- Strong Growth Momentum: Aclarion's Nociscan platform has achieved triple-digit annual growth, indicating accelerated adoption and integration into clinical workflows, thereby enhancing the company's competitive position in the chronic low back pain market.
- Clinical Milestone Progress: The interim results of the CLARITY trial are anticipated in Q4 2026, which will not only advance the company's reimbursement efforts but also potentially boost market recognition and investor confidence.
- IP Enhancement: The new AI patent adds to Aclarion's total of 64 issued and pending patents worldwide, which not only protects its technological innovations but also lays a foundation for future product development and market expansion.
- Financial Stability: Aclarion announced a $2.5 million share repurchase program and has no debt, with cash runway extending into the second half of 2027, demonstrating the sustainability of its long-term growth strategy.
See More
Aclarion Rejects Echo Lake's Acquisition Proposal
- Board Rejects Acquisition Proposal: Aclarion's Board unanimously rejected Echo Lake Capital's unsolicited acquisition proposal at $4 per share, asserting that it significantly undervalues the company's strategic potential and intrinsic value, indicating a disregard for shareholder interests.
- Acquisition Structure Concerns: The Board highlighted that Echo Lake's proposal would allow it to acquire Aclarion's cash and other valuable assets at a substantial discount, thereby harming the interests of other shareholders and reflecting an unreasonable proposal structure.
- Commitment to Value Creation: Aclarion's Board reiterated its commitment to pursuing credible paths for value creation and remains open to any proposals that appropriately reflect the company's intrinsic value, ensuring the interests of all shareholders are protected.
- Technological Background: Aclarion focuses on the chronic low back pain market, leveraging the Nociscan platform to assist physicians in identifying pain sources through magnetic resonance spectroscopy, showcasing the company's innovative capabilities and market potential in healthcare technology.
See More
Aclarion Stockholders Approve All Proposals at Annual Meeting
- Board Elections: At the 2026 Annual Meeting, Aclarion's stockholders elected seven directors, including CEO Brent Ness, to serve until 2027, reflecting strong shareholder confidence in the company's leadership.
- Audit Firm Appointment: Stockholders approved Haynie & Company as the company's independent registered public accounting firm, a decision that will enhance financial transparency and bolster investor confidence.
- Equity Incentive Plan Amendment: The amendment to the 2022 equity incentive plan aims to attract and retain key talent, thereby driving ongoing innovation and growth in the healthcare technology sector.
- Business Growth Highlights: Aclarion achieved a 196% year-over-year increase in Nociscan scan volumes in Q1 2026 and expanded insurance coverage in the UK, indicating robust growth momentum and market recognition in the chronic low back pain sector.
See More
Aclarion Expands Nociscan Availability in Los Angeles Area
- Partnership Agreement: Aclarion has signed an agreement with the Institute of Neuro Innovation in Los Angeles to introduce Nociscan, leveraging Dr. Amir Vokshoor's team to enhance precise treatment decisions for chronic low back pain patients, thereby improving treatment success rates.
- Data Asset Development: By integrating with SPECT-CT, Nociscan will facilitate a comparative study of chemical biomarker data and bone metabolic information, enhancing the accumulation of real-world evidence that supports payer and provider adoption, thus driving the company's growth strategy in the market.
- Market Demand Response: With approximately 266 million people globally affected by chronic low back pain, Aclarion's Nociscan platform serves as the first evidence-supported SaaS solution to noninvasively distinguish between painful and non-painful lumbar discs, addressing the urgent need for precise diagnostic tools in the market.
- Clinical Success Rate Improvement: Nociscan demonstrates a 97% surgical success rate when treating all Nociscan-positive discs, a significant metric that not only boosts physician confidence in treatment but also solidifies Aclarion's leadership position in the chronic low back pain market.
See More
Aclarion Study Reveals Immune Links to Back Pain
- Significant Research Findings: Aclarion's Nociscan technology successfully measured intradiscal propionic acid in an award-winning study, revealing immune-linked patient subtypes associated with back pain, indicating its potential value in chronic pain diagnosis.
- Expanded Clinical Applications: The study suggests that Nociscan may not only assist surgeons in identifying painful discs but also differentiate between mechanical, inflammatory, and immune-related pain sources, thereby advancing personalized treatment strategies.
- Immune Response Association: Findings indicate that elevated propionic acid levels correlate with specific immune activation patterns, particularly involving B-cell activation, suggesting that some back pain patients may be linked to immune responses rather than mere structural degeneration.
- Future Development Potential: Advances in Nociscan's technology may provide clinicians with deeper insights into the biological processes driving pain, opening new avenues for personalized spine care that enhance treatment outcomes and patient quality of life.
See More
Aclarion Responds to Echo Lake's Acquisition Proposal
- Acquisition Proposal Response: Aclarion has responded to Echo Lake Capital's acquisition offer of $4.00 per share, stating that the Board will carefully evaluate the proposal to ensure it aligns with the best interests of the company and all shareholders, thereby protecting shareholder value.
- Share Repurchase Program: The Board has authorized a share repurchase program, indicating a lack of confidence in the current market valuation, with plans to enhance shareholder value through buybacks while continuing to invest in business development to bolster long-term growth potential.
- Board Composition: Aclarion's Board consists of seven highly qualified directors with expertise in healthcare and technology investing, having appointed five new directors in the past six years to ensure diversity and alignment with strategic priorities, thus driving value creation for the company.
- Technological Innovation: Aclarion's Nociscan platform leverages Magnetic Resonance Spectroscopy and augmented intelligence algorithms to non-invasively assist physicians in identifying the sources of chronic low back pain, showcasing the company's innovative capabilities and market potential in the healthcare technology sector.
See More
Aclarion to Present at Planet MicroCap Las Vegas 2026
- Strong Growth Momentum: Aclarion's Nociscan platform has achieved triple-digit annual growth, indicating accelerated adoption and integration into clinical workflows, thereby enhancing the company's competitive position in the chronic low back pain market.
- Clinical Milestone Progress: The interim results of the CLARITY trial are anticipated in Q4 2026, which will not only advance the company's reimbursement efforts but also potentially boost market recognition and investor confidence.
- IP Enhancement: The new AI patent adds to Aclarion's total of 64 issued and pending patents worldwide, which not only protects its technological innovations but also lays a foundation for future product development and market expansion.
- Financial Stability: Aclarion announced a $2.5 million share repurchase program and has no debt, with cash runway extending into the second half of 2027, demonstrating the sustainability of its long-term growth strategy.
See More
Aclarion Rejects Echo Lake's Acquisition Proposal
- Board Rejects Acquisition Proposal: Aclarion's Board unanimously rejected Echo Lake Capital's unsolicited acquisition proposal at $4 per share, asserting that it significantly undervalues the company's strategic potential and intrinsic value, indicating a disregard for shareholder interests.
- Acquisition Structure Concerns: The Board highlighted that Echo Lake's proposal would allow it to acquire Aclarion's cash and other valuable assets at a substantial discount, thereby harming the interests of other shareholders and reflecting an unreasonable proposal structure.
- Commitment to Value Creation: Aclarion's Board reiterated its commitment to pursuing credible paths for value creation and remains open to any proposals that appropriately reflect the company's intrinsic value, ensuring the interests of all shareholders are protected.
- Technological Background: Aclarion focuses on the chronic low back pain market, leveraging the Nociscan platform to assist physicians in identifying pain sources through magnetic resonance spectroscopy, showcasing the company's innovative capabilities and market potential in healthcare technology.
See More
Aclarion Stockholders Approve All Proposals at Annual Meeting
- Board Elections: At the 2026 Annual Meeting, Aclarion's stockholders elected seven directors, including CEO Brent Ness, to serve until 2027, reflecting strong shareholder confidence in the company's leadership.
- Audit Firm Appointment: Stockholders approved Haynie & Company as the company's independent registered public accounting firm, a decision that will enhance financial transparency and bolster investor confidence.
- Equity Incentive Plan Amendment: The amendment to the 2022 equity incentive plan aims to attract and retain key talent, thereby driving ongoing innovation and growth in the healthcare technology sector.
- Business Growth Highlights: Aclarion achieved a 196% year-over-year increase in Nociscan scan volumes in Q1 2026 and expanded insurance coverage in the UK, indicating robust growth momentum and market recognition in the chronic low back pain sector.
See More
Aclarion Expands Nociscan Availability in Los Angeles Area
- Partnership Agreement: Aclarion has signed an agreement with the Institute of Neuro Innovation in Los Angeles to introduce Nociscan, leveraging Dr. Amir Vokshoor's team to enhance precise treatment decisions for chronic low back pain patients, thereby improving treatment success rates.
- Data Asset Development: By integrating with SPECT-CT, Nociscan will facilitate a comparative study of chemical biomarker data and bone metabolic information, enhancing the accumulation of real-world evidence that supports payer and provider adoption, thus driving the company's growth strategy in the market.
- Market Demand Response: With approximately 266 million people globally affected by chronic low back pain, Aclarion's Nociscan platform serves as the first evidence-supported SaaS solution to noninvasively distinguish between painful and non-painful lumbar discs, addressing the urgent need for precise diagnostic tools in the market.
- Clinical Success Rate Improvement: Nociscan demonstrates a 97% surgical success rate when treating all Nociscan-positive discs, a significant metric that not only boosts physician confidence in treatment but also solidifies Aclarion's leadership position in the chronic low back pain market.
See More
Aclarion Study Reveals Immune Links to Back Pain
- Significant Research Findings: Aclarion's Nociscan technology successfully measured intradiscal propionic acid in an award-winning study, revealing immune-linked patient subtypes associated with back pain, indicating its potential value in chronic pain diagnosis.
- Expanded Clinical Applications: The study suggests that Nociscan may not only assist surgeons in identifying painful discs but also differentiate between mechanical, inflammatory, and immune-related pain sources, thereby advancing personalized treatment strategies.
- Immune Response Association: Findings indicate that elevated propionic acid levels correlate with specific immune activation patterns, particularly involving B-cell activation, suggesting that some back pain patients may be linked to immune responses rather than mere structural degeneration.
- Future Development Potential: Advances in Nociscan's technology may provide clinicians with deeper insights into the biological processes driving pain, opening new avenues for personalized spine care that enhance treatment outcomes and patient quality of life.
See More
Aclarion Responds to Echo Lake's Acquisition Proposal
- Acquisition Proposal Response: Aclarion has responded to Echo Lake Capital's acquisition offer of $4.00 per share, stating that the Board will carefully evaluate the proposal to ensure it aligns with the best interests of the company and all shareholders, thereby protecting shareholder value.
- Share Repurchase Program: The Board has authorized a share repurchase program, indicating a lack of confidence in the current market valuation, with plans to enhance shareholder value through buybacks while continuing to invest in business development to bolster long-term growth potential.
- Board Composition: Aclarion's Board consists of seven highly qualified directors with expertise in healthcare and technology investing, having appointed five new directors in the past six years to ensure diversity and alignment with strategic priorities, thus driving value creation for the company.
- Technological Innovation: Aclarion's Nociscan platform leverages Magnetic Resonance Spectroscopy and augmented intelligence algorithms to non-invasively assist physicians in identifying the sources of chronic low back pain, showcasing the company's innovative capabilities and market potential in the healthcare technology sector.
See More
